SCSC Form 144 Notice: Insider Plans to Sell 4,402 Shares via Merrill Lynch
Rhea-AI Filing Summary
Form 144 summary for Scansource, Inc. (SCSC): The filer proposes to sell 4,402 shares of Scansource common stock through Merrill Lynch on 08/27/2025 on NASDAQ. The reported aggregate market value of the shares to be sold is $190,474.54 based on 21,884,508 shares outstanding. These shares were acquired through restricted stock unit vesting on 08/25/2025 (1,012 shares), 08/26/2025 (1,080 shares), 08/27/2025 (1,214 shares), and 08/30/2025 (1,096 shares), with compensatory payment noted at each vesting date. The filer also reported a prior sale by Rachel Hayden of 6,738 shares on 06/20/2025 for gross proceeds of $278,077.26. The filer attests there is no material nonpublic information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider sale under Rule 144; modest size relative to shares outstanding, appears procedural rather than market-moving.
The filing documents a proposed sale of 4,402 shares valued at $190,474.54 to occur through Merrill Lynch on NASDAQ on 08/27/2025. The shares originate from recent RSU vesting events across four dates and are described as compensatory payments. Given the company's outstanding share count of 21,884,508, the transaction represents a small fraction of total equity and is consistent with routine insider liquidity following compensation vesting. The filing also discloses a prior insider sale of 6,738 shares on 06/20/2025 for $278,077.26. No earnings, debt, or operational metrics are provided in this notice to assess broader financial impact.
TL;DR: Compliance-focused filing documenting RSU-derived share sales; it affirms Rule 144 procedures and insider attestation regarding material nonpublic information.
The notice shows adherence to Rule 144 procedures by identifying the broker, proposed sale date, share counts, acquisition method, and previous insider sales. Acquisition details specify that all 4,402 shares arose from restricted stock unit vesting and were treated as compensatory payments on the listed dates, which is standard for executive or employee equity compensation. The signer asserts no undisclosed material adverse information, a required certification for such notices. This is a routine governance disclosure rather than a corporate event requiring material investor action.